Please login to the form below

Cephalon

This page shows the latest Cephalon news and features for those working in and with pharma, biotech and healthcare.

Two other investigations - involving AstraZeneca/Nycomed and Teva/Cephalon - did not result in enforcement action by the Commission.

US government probes Lilly and Merck over drug pricing

In July both AstraZeneca (AZ) and Cephalon settled an action brought by the US government which accused them of underpaying. ... AZ paid nearly $47m to settle the cases, with Cephalon stumping up $7.5m, and at the time the DoJ said it would "continue to
Teva hit with $1.2bn pay-for-delay fine

Israeli-based Teva has reached a settlement resolving the Commission's antitrust suit charging its subsidiary Cephalon, with illegally blocking generic competition to its blockbuster sleep-disorder drug Provigil (modafinil). ... As part of the settlement,
Teva slapped with $512m fine on pay-for-delay deal

Teva is paying $512m to settle a legal case against its subsidiary Cephalon used pay-for-delay tactics on its wakefulness drug Provigil (modafinil). ... cases. The lawsuit, originally filed in 2006 by drug wholesalers and retailers that buy directly from
EU hits Servier and generic firms with €428m 'pay-for-delay' fine

Meanwhile, antitrust investigators in the EU are still looking at possible collusion between Teva and Cephalon, which is now owned by the Israeli company, concerning narcolepsy treatment Provigil (modafinil), while a
Global biosimilars market “will see exponential growth”

Biosimilar companies can reduce their market access time by linking with other companies with expertise in biosimilars manufacturing and development, Sashidhar added, citing Teva's alliance with Cephalon and Lupin Pharmaceuticals'

More from news
Approximately 1 fully matching, plus 68 partially matching documents found.

Pharma deals in May 2015

This has proved to be the case following Teva's purchase of Cephalon in May 2011 for $6.2bn which brought Provigil (modafinil for sleep disorders) into the portfolio.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Pfizer’s Elizabeth Barrett joins Novartis as its oncology head

Prior to her time with Pfizer, Barrett held roles with Cephalon andchief executive officer at Novartis, said: “Liz is a highly accomplished and recognised oncology and people leader with an impressive
Martin Reeves joins Oxford BioDynamics

His career to date has seen him hold positions such as head of business development, global branded products at Teva Pharmaceuticals, VP of business development and strategic planning at Cephalon and
Srdjan Stankovic joins Acadia Pharmaceuticals

Prior to this he worked at Teva as senior vice president and head of global clinical development following that company's acquisition of Cephalon, where he was senior vice president, worldwide
Bruce Peacock joins Dicerna from Ophthotech

of Cephalon and chief financial officer of Centocor.
Paul Blake joins Oxford BioMedica

His career includes senior managed roles at Cephalon and a senior VP position at SmithKline Beecham Pharmaceuticals, now GSK.

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Add my company

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Route 66: can remote working put two-thirds of us back on the road to engaged employment?: Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
Demonstrating the value of HCP self-serve portals: Develop the art of setting KPIs and metrics aligned to your specific objectives, target personas, key educational messages, content, website features and journeys....